Jagsonpal Income Before Tax from 2010 to 2024

JAGSNPHARM   636.65  9.80  1.52%   
Jagsonpal Pharmaceuticals' Income Before Tax is increasing with slightly volatile movements from year to year. Income Before Tax is estimated to finish at about 313.6 M this year. For the period between 2010 and 2024, Jagsonpal Pharmaceuticals, Income Before Tax quarterly trend regression had median of  94,148,000 and r-value of  0.75. View All Fundamentals
 
Income Before Tax  
First Reported
2011-09-30
Previous Quarter
71.1 M
Current Value
153.7 M
Quarterly Volatility
43.5 M
 
Yuan Drop
 
Covid
Check Jagsonpal Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jagsonpal Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 14.6 M, Interest Expense of 7.7 M or Total Revenue of 1.8 B, as well as many indicators such as . Jagsonpal financial statements analysis is a perfect complement when working with Jagsonpal Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement various Jagsonpal Pharmaceuticals Technical models . Check out the analysis of Jagsonpal Pharmaceuticals Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Jagsonpal Stock

Jagsonpal Pharmaceuticals financial ratios help investors to determine whether Jagsonpal Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Jagsonpal with respect to the benefits of owning Jagsonpal Pharmaceuticals security.